Reata Pharmaceuticals, Inc.
RETA · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -0.27 | -0.34 | -0.75 |
| FCF Yield | -1.66% | -2.43% | -3.68% | -5.11% |
| EV / EBITDA | 22.50 | -30.79 | -12.43 | -15.09 |
| Quality | ||||
| ROIC | 50.80% | -26.20% | -15.61% | -12.74% |
| Gross Margin | 96.28% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -0.36 | 0.70 | 0.59 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | 46.50% | -34.58% | -29.73% | -28.17% |
| Free Cash Flow Growth | 13.96% | -60.63% | -8.36% | 8.80% |
| Safety | ||||
| Net Debt / EBITDA | 0.61 | -0.30 | -0.66 | -1.60 |
| Interest Coverage | 24.21 | -10.03 | -6.52 | -6.62 |
| Efficiency | ||||
| Inventory Turnover | 0.29 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,710.12 | 0.00 | 0.00 | 0.00 |